Imaging Study of Glioblastomas Treated With Avastin

Study Overview
=================
Brief Summary
-----------------
This study aims to assess the effect of Avastin on brain vascularity and blood-brain permeability using dynamic contrast ct scans (DECT) and MRI imaging. Previous publications have documented the method by which DECT can determine alterations in vascular volume and tissue permeability within tumors and normal brain tissue. Functional maps of cerebral blood flow cerebral blood volume and permeability-surface area can be generated from the DECT studies to assess tumor perfusion. MRI spectroscopy analyzes brain chemistry to detect tumour versus edema versus normal brain. Thirty patients will receive MRI spectroscopy and DECT imaging at the time of presumed recurrence and 3 months later. 15 patients who do not receive Avastin and 15 patients who do receive Avastin as standard treatment for recurrence will be studied with DECT and MRI spectroscopy at baseline and then again in 3 months.

Detailed Description
-----------------
The clinical determination of the point of tumour progression or response is difficult to determine using standard diagnostic imaging ie CT/MRI especially following previous treatment with surgery, radiation and chemotherapy. Hemorrhage, edema, inflammation and vascular necrosis. Both MR spectroscopy and DECT have been reported as being able to define areas of recurrent tumour as opposed to treatment-related effects. We wish to investigate the correlation between MR spectroscopy and DECT in assessing tumour progression or response to Avastin in comparison with patients not receiving Avastin. Health Canada has approved Avastin for clinical use in patients with recurrent glioblastoma who have previously received temozolomide and radiotherapy. We propose to perform a DECT scan at baseline at presumed tumour progression and again 3 months to determine the effects of tumour progression/response on blood brain barrier permeability and vascular volume. The group of 15 patients will be compared to a group of 15 patients who do not receive Avastin at recurrence involving DECT scanning and MR spectroscopy at the time of the radiological progression and 3 months later.

Official Title
-----------------
Feasibility Study of Magnetic Resonance Spectroscopy and Dynamic Enhanced Cat Scan Imaging in Glioblastomas Treated With and Without Avastin

Conditions
-----------------
Malignant Gliomas

Intervention / Treatment
-----------------
* Device: DECT
* Device: MR spectroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histological diagnosis of glioblastoma with clinical or radiological evidence of progression as indicated by the RANO criteria 19 Previous radiation and temozolomide chemotherapy Patients must be receiving Avastin chemotherapy as second-line treatment if in the Avastin group Study-specific consent Exclusion Criteria: Failure to meet inclusion criteria Pregnant or lactating patients Allergy to iodine or CT contrast precludes DECT component of study Claustrophobia precludes MR Spectroscopy component of study Internal metal which would preclude an MRI scan

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: DECT/MR Spectroscopy +Avastin<br>-15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later | Device: DECT<br>* DECT at tumor progression and 3 months later<br>* Other names: 3 T 64-slice CT scanner (Discovery CT750 HD, GE Healthcare;Device: MR spectroscopy<br>* MR spectroscopy at tumor progression and 3 months later<br>* Other names: Analysis software: Brain voyager;|
| Active Comparator: DECT/MR Spectroscopy no Avastin<br>15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1 | Device: DECT<br>* DECT at tumor progression and 3 months later<br>* Other names: 3 T 64-slice CT scanner (Discovery CT750 HD, GE Healthcare;Device: MR spectroscopy<br>* MR spectroscopy at tumor progression and 3 months later<br>* Other names: Analysis software: Brain voyager;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3 Month Response | participants who had reduction of tumor size from avastin at 3 months | at 3 months after initial DECT and MR spectroscopy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dynamic enhanced ct scan, mri spectroscopy, recurrent gliomas